WO2009155055A3 - Méthodes de réalisation de la signalisation du wnt par analyse structurelle du dkk - Google Patents

Méthodes de réalisation de la signalisation du wnt par analyse structurelle du dkk Download PDF

Info

Publication number
WO2009155055A3
WO2009155055A3 PCT/US2009/045485 US2009045485W WO2009155055A3 WO 2009155055 A3 WO2009155055 A3 WO 2009155055A3 US 2009045485 W US2009045485 W US 2009045485W WO 2009155055 A3 WO2009155055 A3 WO 2009155055A3
Authority
WO
WIPO (PCT)
Prior art keywords
dkk
methods
effecting
wnt signaling
structural analysis
Prior art date
Application number
PCT/US2009/045485
Other languages
English (en)
Other versions
WO2009155055A2 (fr
Inventor
Jie Zheng
Original Assignee
Enzo Biochem, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzo Biochem, Inc. filed Critical Enzo Biochem, Inc.
Priority to EP09767366.9A priority Critical patent/EP2303303B1/fr
Publication of WO2009155055A2 publication Critical patent/WO2009155055A2/fr
Publication of WO2009155055A3 publication Critical patent/WO2009155055A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

L'invention porte sur des compositions et méthodes liées à la régulation de la signalisation du Wnt par des polypeptides de Dickkopf (Dkk), et sur des maladies associées au Wnt, et par exemple, sur des composés analogues aux polypeptides Dkk ou LRP. L'invention porte également sur des composés qui rompent la liaison entre un polypeptide Dkk et un polypeptide LRP et sur des méthodes d'utilisation des composés et compositions décrits.
PCT/US2009/045485 2008-05-28 2009-05-28 Méthodes de réalisation de la signalisation du wnt par analyse structurelle du dkk WO2009155055A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09767366.9A EP2303303B1 (fr) 2008-05-28 2009-05-28 Méthodes de réalisation de la signalisation du wnt par analyse structurelle du dkk

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13009808P 2008-05-28 2008-05-28
US61/130,098 2008-05-28
US12/454,758 US8716243B2 (en) 2008-05-28 2009-05-22 Methods of effecting Wnt signaling through Dkk structural analysis
US12/454,758 2009-05-22

Publications (2)

Publication Number Publication Date
WO2009155055A2 WO2009155055A2 (fr) 2009-12-23
WO2009155055A3 true WO2009155055A3 (fr) 2010-05-27

Family

ID=41434649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/045485 WO2009155055A2 (fr) 2008-05-28 2009-05-28 Méthodes de réalisation de la signalisation du wnt par analyse structurelle du dkk

Country Status (3)

Country Link
US (1) US8716243B2 (fr)
EP (2) EP2303303B1 (fr)
WO (1) WO2009155055A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428583B2 (en) 2010-05-06 2016-08-30 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
EP2514765A1 (fr) * 2011-04-18 2012-10-24 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Gpr177 en tant que cible et marqueur des tumeurs
TW201323442A (zh) 2011-11-04 2013-06-16 Novartis Ag 低密度脂蛋白相關蛋白６（ｌｒｐ６）－半衰期延長構築體
WO2016126054A1 (fr) * 2015-02-04 2016-08-11 (주)메드팩토 Composition pour prévenir ou traiter un trouble de l'érection comprenant une protéine dkk2 modifiée ou un gène pour celle-ci, et son procédé d'utilisation
KR20200011933A (ko) 2017-05-31 2020-02-04 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드
US11572394B2 (en) * 2020-02-16 2023-02-07 Pasteur Institute Of Iran Peptides for targeting LRP6-overexpressed cells

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020161178A1 (en) * 1998-09-25 2002-10-31 Amgen Inc. Novel DKR polypeptides
US20030068312A1 (en) * 1997-04-16 2003-04-10 Millennium Pharmaceuticals, Inc. Novel human dickkopf-related protein and nucleic acid molecules and uses therefor
US20030165500A1 (en) * 2001-05-01 2003-09-04 Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030211588A1 (en) * 2000-05-08 2003-11-13 Parris Kevin Delos Methods for identifying agents that interact with an active site
WO2003106657A2 (fr) * 2002-06-14 2003-12-24 Stowers Institute For Medical Research Sequences nucleotidiques et sequences d'acides amines wise/sost
US20040072362A1 (en) * 2002-06-05 2004-04-15 Pharmacia & Upjohn Company Methods for identifying ligands using competitive binding 1H NMR experiments
US20040244069A1 (en) * 2001-05-11 2004-12-02 Wyeth Transgenic animal model of bone mass modulation
US20060127393A1 (en) * 2004-08-04 2006-06-15 Amgen Inc. Antibodies to Dkk-1
US20060183157A1 (en) * 2005-02-07 2006-08-17 David Cowburn Methods and devices for characterizing macromolecular complexes using isotope labeling techniques
US20060198791A2 (en) * 2003-09-22 2006-09-07 Dianqing Wu Compositions and Methods for Bone Formation and Remodeling
US20070020642A1 (en) * 2003-07-03 2007-01-25 Zhan Deng Structural interaction fingerprint
US20070128187A1 (en) * 2001-05-17 2007-06-07 Genome Therapeutics Corporation Reagents and method for modulating Dkk-mediated interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446859A1 (fr) * 2001-05-11 2002-11-21 Wyeth Modele de modulation de la masse osseuse d'un'animal transgenique
US20040014209A1 (en) * 2002-01-23 2004-01-22 Lassar Andrew B. Compositions and methods for modulating cell differentiation
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US20120178697A9 (en) 2003-09-22 2012-07-12 Jie Zheng Compositions and methods for the inhibition of dishevelled proteins
US20100041599A1 (en) 2006-11-14 2010-02-18 Dakai Liu Compositions and methods for bone formation, bone remodeling and toxin protection
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068312A1 (en) * 1997-04-16 2003-04-10 Millennium Pharmaceuticals, Inc. Novel human dickkopf-related protein and nucleic acid molecules and uses therefor
US20020161178A1 (en) * 1998-09-25 2002-10-31 Amgen Inc. Novel DKR polypeptides
US20030211588A1 (en) * 2000-05-08 2003-11-13 Parris Kevin Delos Methods for identifying agents that interact with an active site
US20030165500A1 (en) * 2001-05-01 2003-09-04 Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20040244069A1 (en) * 2001-05-11 2004-12-02 Wyeth Transgenic animal model of bone mass modulation
US20070128187A1 (en) * 2001-05-17 2007-06-07 Genome Therapeutics Corporation Reagents and method for modulating Dkk-mediated interactions
US20040072362A1 (en) * 2002-06-05 2004-04-15 Pharmacia & Upjohn Company Methods for identifying ligands using competitive binding 1H NMR experiments
WO2003106657A2 (fr) * 2002-06-14 2003-12-24 Stowers Institute For Medical Research Sequences nucleotidiques et sequences d'acides amines wise/sost
US20070020642A1 (en) * 2003-07-03 2007-01-25 Zhan Deng Structural interaction fingerprint
US20060198791A2 (en) * 2003-09-22 2006-09-07 Dianqing Wu Compositions and Methods for Bone Formation and Remodeling
US20060127393A1 (en) * 2004-08-04 2006-06-15 Amgen Inc. Antibodies to Dkk-1
US20060183157A1 (en) * 2005-02-07 2006-08-17 David Cowburn Methods and devices for characterizing macromolecular complexes using isotope labeling techniques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI ET AL.: "Mesd Binds to Mature LDL-Receptor-Related Protein-6 and Antagonizes Ligand Binding.", JOUMAL OF CELL SCIENCE., vol. 118, no. 22, November 2005 (2005-11-01), pages 5305 - 5314, XP008120944 *
See also references of EP2303303A4 *
WANG ET AL.: "Characterization of the Kremen-binding Site on Dkk1 and Elucidation of the Role o Kremen in Dkk-mediated Wnt Antagonism.", THE JOUMAL OF BIOLOGICAL CHEMISTRY EPUB JBC PAPERS IN PRESS, vol. 283, no. 34, 23 May 2008 (2008-05-23), pages 23371 - 23375, XP008141236 *

Also Published As

Publication number Publication date
EP2303303A2 (fr) 2011-04-06
EP2303303A4 (fr) 2012-02-22
EP2303303B1 (fr) 2017-01-25
EP3170838A1 (fr) 2017-05-24
US8716243B2 (en) 2014-05-06
US20090312253A1 (en) 2009-12-17
WO2009155055A2 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
EP4004811A4 (fr) Technologies d'analyse de contenu
WO2009155055A3 (fr) Méthodes de réalisation de la signalisation du wnt par analyse structurelle du dkk
WO2017069628A3 (fr) Molécules de liaison inhibant la croissance de cancer
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
EP2275431A3 (fr) Purification améliorée de biomolécules phosphorylées et non phosphorylées par chromatographie sur hydroxyapati
WO2010009368A3 (fr) Compositions pour la détection et le traitement du cancer colorectal
WO2010040508A8 (fr) Anticorps anti-vegf/anti-ang-2 bispécifiques
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2013119966A3 (fr) Anticorps et autres hétéromultimères monocaténaires
WO2010145792A8 (fr) Protéines bispécifiques se liant à un antigène
WO2008121767A3 (fr) Polypeptides cousus
WO2008133722A3 (fr) Anticorps et diagnostics
WO2010037041A3 (fr) Agents se liant aux récepteurs frizzled et leurs utilisations
WO2017106684A3 (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
WO2011047087A3 (fr) Détection de protéine par l'intermédiaire de nanorapporteurs
WO2010077740A3 (fr) Nouveaux composés antiviraux, compositions et procédés d'utilisation
WO2011123785A3 (fr) Agents de liaison aux récepteurs frizzled et leurs utilisations
WO2009026117A3 (fr) Nouveaux composés
WO2009059304A3 (fr) Composés pour traiter une prolifération cellulaire anormale
WO2013138793A3 (fr) Réactifs d'affinité pour la purification de protéines
WO2009067578A3 (fr) Nouveaux activateurs du récepteur de la vitamine d et procédés de fabrication
DK1893030T3 (da) Fremgangsmåde til fremstilling af fødevarer ved ko-ekstrudering, især pølser, og fødevarer, der opnås ved denne fremgangsmåde
WO2011077099A3 (fr) Procédés de purification de cucurbiturile
WO2011130603A3 (fr) Anticorps anti-vla-4
WO2010121093A3 (fr) Compositions d'anticorps humanisés et procédés de liaison d'acide lysophosphatidique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09767366

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009767366

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009767366

Country of ref document: EP